News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
539,406 Results
Type
Article (36891)
Company Profile (76)
Press Release (502431)
Multimedia
Podcasts (65)
Webinars (14)
Section
Business (146706)
Career Advice (2395)
Deals (26742)
Drug Delivery (104)
Drug Development (70702)
Employer Resources (135)
FDA (13290)
Job Trends (11656)
News (261982)
Policy (25925)
Tag
2027 Genetown Elite (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (2)
Academia (2423)
Accelerated approval (30)
Adcomms (29)
Allergies (128)
Alliances (36544)
ALS (160)
Alzheimer's disease (1631)
Antibody-drug conjugate (ADC) (292)
Approvals (13512)
Artificial intelligence (451)
Autoimmune disease (129)
Automation (33)
Bankruptcy (302)
Best Places to Work (9515)
BIOSECURE Act (15)
Biosimilars (165)
Biotechnology (57)
Bladder cancer (149)
Brain cancer (53)
Breast cancer (581)
Cancer (4368)
Cardiovascular disease (388)
Career advice (2029)
Career pathing (36)
CAR-T (242)
CDC (39)
Cell therapy (656)
Cervical cancer (27)
Clinical research (60850)
Collaboration (1374)
Company closure (4)
Compensation (484)
Complete response letters (56)
COVID-19 (2470)
CRISPR (76)
C-suite (833)
Cystic fibrosis (114)
Data (5785)
Decentralized trials (2)
Denatured (10)
Depression (139)
Diabetes (465)
Diagnostics (5779)
Digital health (34)
Diversity (8)
Diversity, equity & inclusion (39)
Drug discovery (205)
Drug pricing (166)
Drug shortages (24)
Duchenne muscular dystrophy (219)
Earnings (56252)
Editorial (53)
Employer branding (17)
Employer resources (126)
Events (74481)
Executive appointments (958)
FDA (16052)
Fibrodysplasia Ossificans Progressiva (6)
Friedreich's ataxia (10)
Frontotemporal dementia (21)
Funding (1204)
Gene editing (166)
Generative AI (39)
Gene therapy (564)
GLP-1 (920)
Government (4199)
Grass and pollen (7)
Guidances (376)
Healthcare (15379)
HIV (52)
Huntington's disease (41)
IgA nephropathy (80)
Immunology and inflammation (249)
Immuno-oncology (47)
Indications (92)
Infectious disease (2708)
Inflammatory bowel disease (171)
Inflation Reduction Act (13)
Influenza (94)
Intellectual property (219)
Interviews (521)
IPO (12138)
IRA (47)
Job creations (2428)
Job search strategy (1636)
JPM (54)
Kidney cancer (17)
Labor market (54)
Layoffs (484)
Leadership (36)
Legal (5414)
Liver cancer (88)
Longevity (10)
Lung cancer (628)
Lymphoma (348)
Machine learning (32)
Management (51)
Manufacturing (635)
MASH (173)
Medical device (10486)
Medtech (10528)
Mergers & acquisitions (15517)
Metabolic disorders (1193)
Multiple sclerosis (145)
NASH (22)
Neurodegenerative disease (303)
Neuropsychiatric disorders (92)
Neuroscience (2798)
Neurotech (1)
NextGen: Class of 2026 (5223)
Non-profit (3818)
Now hiring (53)
Obesity (544)
Opinion (256)
Ovarian cancer (146)
Pain (185)
Pancreatic cancer (202)
Parkinson's disease (263)
Partnered (28)
Patents (441)
Patient recruitment (439)
Peanut (46)
People (50733)
Pharmaceutical (19)
Pharmacy benefit managers (17)
Phase 1 (18735)
Phase 2 (26782)
Phase 3 (20451)
Pipeline (4745)
Policy (257)
Postmarket research (2198)
Preclinical (7549)
Press Release (53)
Prostate cancer (215)
Psychedelics (54)
Radiopharmaceuticals (234)
Rare diseases (762)
Real estate (3839)
Recruiting (53)
Regulatory (20246)
Reports (30)
Research institute (2041)
Resumes & cover letters (345)
Rett syndrome (25)
RNA editing (15)
RSV (66)
Schizophrenia (148)
Series A (203)
Series B (151)
Service/supplier (2)
Sickle cell disease (90)
Special edition (17)
Spinal muscular atrophy (153)
Sponsored (35)
Startups (2572)
State (2)
Stomach cancer (18)
Supply chain (85)
Tariffs (71)
The Weekly (54)
Vaccines (872)
Venture capital (75)
Weight loss (361)
Women's health (66)
Worklife (19)
Date
Last 7 days (484)
Last 30 days (1657)
Last 365 days (25265)
2026 (2365)
2025 (25614)
2024 (29338)
2023 (33031)
2022 (43275)
2021 (46257)
2020 (44759)
2019 (38059)
2018 (28839)
2017 (25870)
2016 (24457)
2015 (28633)
2014 (21272)
2013 (17137)
2012 (18309)
2011 (19387)
2010 (17118)
Location
Africa (695)
Alabama (74)
Alaska (4)
Arizona (200)
Arkansas (11)
Asia (33452)
Australia (7057)
California (8818)
Canada (2870)
China (985)
Colorado (368)
Connecticut (362)
Delaware (305)
Europe (74529)
Florida (1445)
Georgia (289)
Hawaii (1)
Idaho (47)
Illinois (704)
India (56)
Indiana (427)
Iowa (17)
Japan (376)
Kansas (105)
Kentucky (28)
Louisiana (23)
Maine (57)
Maryland (1173)
Massachusetts (6000)
Michigan (273)
Minnesota (465)
Mississippi (4)
Missouri (115)
Montana (23)
Nebraska (24)
Nevada (106)
New Hampshire (71)
New Jersey (2577)
New Mexico (21)
New York (2400)
North Carolina (1117)
North Dakota (6)
Northern California (4260)
Ohio (260)
Oklahoma (10)
Oregon (26)
Pennsylvania (1815)
Puerto Rico (22)
Rhode Island (35)
South America (947)
South Carolina (59)
South Dakota (1)
Southern California (3530)
Tennessee (138)
Texas (1447)
United States (31712)
Utah (285)
Vermont (1)
Virginia (224)
Washington D.C. (64)
Washington State (746)
West Virginia (4)
Wisconsin (78)
Wyoming (2)
539,406 Results for "optinose as".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Mergers & acquisitions
Paratek Broadens Portfolio With OptiNose Buy Worth up to $330M
Paratek Pharmaceuticals is betting that OptiNose’s chronic rhinosinusitis treatment will be a partner to its antibiotic treatment Nuzyra.
March 20, 2025
·
1 min read
·
Dan Samorodnitsky
Press Releases
Paratek Pharmaceuticals Completes Acquisition of Optinose, Creating an Expanded Portfolio of Specialty Therapies
May 21, 2025
·
10 min read
Pharm Country
Optinose Announces $55 Million Registered Direct Offering
Optinose announced that it has entered into agreements for the sale of approximately $55 million of its common stock and pre-funded common stock warrants to a group of existing and new institutional investors in a registered direct offering.
May 9, 2024
·
8 min read
Press Releases
Optinose Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Operational Highlights
March 27, 2025
·
8 min read
Press Releases
Optinose Announces Reporting Date for Fourth Quarter and Full Year 2024 Financial Results
March 12, 2025
·
1 min read
Business
Optinose Reports First Quarter 2024 Financial Results and Recent Operational Highlights
Optinose, a pharmaceutical company focused on patients treated by ear, nose and throat and allergy specialists, reported financial results for the quarter ended March 31, 2024, and provided recent operational highlights.
May 14, 2024
·
11 min read
Press Releases
Paratek Pharmaceuticals to Acquire Optinose, Creating Significant Commercial Expansion Opportunities for XHANCE® in Chronic Rhinosinusitis (CRS)
March 20, 2025
·
17 min read
Business
Optinose Announces Reporting Date for First Quarter 2024 Financial Results
Optinose, a pharmaceutical company focused on patients treated by ear, nose and throat and allergy specialists, announced the Company will report financial results for the first quarter 2024 and corporate updates, before market open, on Tuesday, May 14, 2024.
May 10, 2024
·
1 min read
Pharm Country
Optinose to Present at the Needham Virtual Healthcare Conference - April 04, 2024
Optinose announced that members of its management team will present a company overview and business update at the Needham Virtual Healthcare Conference on April 10, 2024 at 2:15 p.m. ET.
April 4, 2024
·
1 min read
Press Releases
Optinose to Present at the Piper Sandler 36th Annual Healthcare Conference
December 3, 2024
·
1 min read
1 of 53,941
Next
